Analysts expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce earnings of ($0.12) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.07). Conatus Pharmaceuticals reported earnings per share of ($0.17) during the same quarter last year, which indicates a positive year over year growth rate of 29.4%. The company is expected to report its next quarterly earnings results on Wednesday, May 1st.
Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Conatus Pharmaceuticals had a negative return on equity of 82.49% and a negative net margin of 53.62%. The business had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $8.63 million.
A number of hedge funds have recently made changes to their positions in CNAT. Two Sigma Investments LP boosted its position in shares of Conatus Pharmaceuticals by 761.1% in the 4th quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock valued at $433,000 after purchasing an additional 221,044 shares during the period. BlackRock Inc. boosted its position in shares of Conatus Pharmaceuticals by 13.4% in the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after purchasing an additional 191,287 shares during the period. Hikari Power Ltd acquired a new position in shares of Conatus Pharmaceuticals in the 4th quarter valued at $289,000. Sofinnova Investments Inc. boosted its position in shares of Conatus Pharmaceuticals by 18.4% in the 4th quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock valued at $1,104,000 after purchasing an additional 99,282 shares during the period. Finally, Wedbush Securities Inc. acquired a new position in shares of Conatus Pharmaceuticals in the 1st quarter valued at $46,000. 27.41% of the stock is owned by institutional investors and hedge funds.
CNAT stock traded up $0.12 during trading hours on Friday, hitting $0.83. 2,624,833 shares of the stock traded hands, compared to its average volume of 1,736,256. Conatus Pharmaceuticals has a one year low of $0.69 and a one year high of $6.74. The stock has a market capitalization of $25.15 million, a P/E ratio of -1.41 and a beta of 3.27.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Story: Why is the LIBOR significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.